Russell Investments Group
TCON

Russell Investments Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Russell Investments Group’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-229
Closed -$105K – 2979
2018
Q1 		$105K Buy
229
+83
+57% +$45.3K ﹤0.01% 2746
2017
Q4 		$93K Buy
+146
New +$88.1K ﹤0.01% 2790

Other funds holding TCON

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Russell Investments Group's TCON Position: Q2 2018 in Review

Russell Investments Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2018, closing a stake of 229 shares — an estimated $105K sold.

Russell Investments Group first reported a position in TCON in Q4 2017 and held it in 2 quarters. The position peaked at $105K in Q1 2018. 34 funds tracked by Wall St. Rank hold TCON as of Q2 2018.

  • Russell Investments Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Russell Investments Group sold 229 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $105K.
  • Russell Investments Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Russell Investments Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $105K in Q1 2018.
  • 34 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Russell Investments Group's 13F filing for Q2 2018, filed 8 Aug 2018.